Trial Profile
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Craniopharyngioma
- Focus Therapeutic Use
- 25 Jan 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 08 Jun 2021 Results (n=16) evaluating the efficacy of BRAF/MEK inhibition in patients (pts) with previously untreated papillary craniopharyngiomas presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 25 May 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Oct 2023.